                         SEQUENCE LISTING

<110>  ULTRAHUMAN TWO LIMITED
 
<120>  CD47 BINDING AGENTS

<130>  ULTW-001/02WO 332945-2003

<150>  GB 1813693.7
<151>  2018-08-22

<150>  GB 1804860.3
<151>  2018-03-27

<160>  333   

<170>  PatentIn version 3.5

<210>  1
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  VH1.8/VL1.6 heavy chain variable (VH) region

<400>  1

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 
            20                  25                  30          


Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Thr Ile Tyr Pro Gly Asn Asp Asp Thr Lys Tyr Asn Gln Lys Phe 
    50                  55                  60                  


Gln Gly Arg Val Thr Ile Thr Ala Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Gly Gly Phe Arg Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu 
            100                 105                 110         


Val Thr Val Ser Ser 
        115         


<210>  2
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  VH1.8/VL1.6 light chain variable (VL) region

<400>  2

Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 
1               5                   10                  15      


Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser 
            20                  25                  30          


Asn Ala Asn Thr Tyr Leu Gly Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Leu Leu Ile Tyr Lys Gly Ser Asn Arg Phe Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Phe Gln Ala 
                85                  90                  95      


Ser His Val Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  3
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  VH1.8/VL1.6-DI heavy chain variable (VH) region

<400>  3

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 
            20                  25                  30          


Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Thr Ile Tyr Pro Gly Asn Asp Asp Thr Lys Tyr Asn Gln Lys Phe 
    50                  55                  60                  


Gln Gly Arg Val Thr Ile Thr Ala Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Gly Gly Phe Arg Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu 
            100                 105                 110         


Val Thr Val Ser Ser 
        115         


<210>  4
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  VH1.8/VL1.6-DI light chain variable (VL) region

<400>  4

Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 
1               5                   10                  15      


Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser 
            20                  25                  30          


Asn Ala Asn Thr Tyr Leu Gly Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Leu Ala Ile Tyr Lys Gly Ser Asn Arg Phe Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Ala Gly Val Tyr Tyr Cys Phe Gln Ala 
                85                  90                  95      


Ser His Val Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  5
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  VH1.8/VL1.1 heavy chain variable (VH) region

<400>  5

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 
            20                  25                  30          


Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Thr Ile Tyr Pro Gly Asn Asp Asp Thr Lys Tyr Asn Gln Lys Phe 
    50                  55                  60                  


Gln Gly Arg Val Thr Ile Thr Ala Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Gly Gly Phe Arg Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu 
            100                 105                 110         


Val Thr Val Ser Ser 
        115         


<210>  6
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  VH1.8/VL1.1 light chain variable (VL) region

<400>  6

Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 
1               5                   10                  15      


Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Gly Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Leu Leu Ile Tyr Lys Gly Ser Asn Arg Phe Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Phe Gln Ala 
                85                  90                  95      


Ser His Val Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  7
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  VH1.8/VL1.5 heavy chain variable (VH) region

<400>  7

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 
            20                  25                  30          


Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Thr Ile Tyr Pro Gly Asn Asp Asp Thr Lys Tyr Asn Gln Lys Phe 
    50                  55                  60                  


Gln Gly Arg Val Thr Ile Thr Ala Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Gly Gly Phe Arg Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu 
            100                 105                 110         


Val Thr Val Ser Ser 
        115         


<210>  8
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  VH1.8/VL1.5 light chain variable (VL) region

<400>  8

Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 
1               5                   10                  15      


Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser 
            20                  25                  30          


Asn Ala Tyr Asn Tyr Leu Gly Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Leu Leu Ile Tyr Lys Gly Ser Asn Arg Phe Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Phe Gln Ala 
                85                  90                  95      


Ser His Val Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  9
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  VH1.8/VL1.4 heavy chain variable (VH) region

<400>  9

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 
            20                  25                  30          


Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Thr Ile Tyr Pro Gly Asn Asp Asp Thr Lys Tyr Asn Gln Lys Phe 
    50                  55                  60                  


Gln Gly Arg Val Thr Ile Thr Ala Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Gly Gly Phe Arg Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu 
            100                 105                 110         


Val Thr Val Ser Ser 
        115         


<210>  10
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  VH1.8/VL1.4 light chain variable (VL) region

<400>  10

Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 
1               5                   10                  15      


Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser 
            20                  25                  30          


Asn Ala Tyr Asn Tyr Leu Gly Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Leu Leu Ile Tyr Lys Gly Ser Asn Arg Phe Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Phe Gln Ala 
                85                  90                  95      


Ser Gln Val Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  11
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  VH1.8/VL1.3 heavy chain variable (VH) region

<400>  11

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 
            20                  25                  30          


Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Thr Ile Tyr Pro Gly Asn Asp Asp Thr Lys Tyr Asn Gln Lys Phe 
    50                  55                  60                  


Gln Gly Arg Val Thr Ile Thr Ala Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Gly Gly Phe Arg Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu 
            100                 105                 110         


Val Thr Val Ser Ser 
        115         


<210>  12
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  VH1.8/VL1.3 light chain variable (VL) region

<400>  12

Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 
1               5                   10                  15      


Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser 
            20                  25                  30          


Asn Ala Asn Thr Tyr Leu Gly Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Leu Leu Ile Tyr Lys Gly Ser Asn Arg Phe Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Phe Gln Ala 
                85                  90                  95      


Ser Gln Val Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  13
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  VH1.8/VL1.2 heavy chain variable (VH) region

<400>  13

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 
            20                  25                  30          


Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Thr Ile Tyr Pro Gly Asn Asp Asp Thr Lys Tyr Asn Gln Lys Phe 
    50                  55                  60                  


Gln Gly Arg Val Thr Ile Thr Ala Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Gly Gly Phe Arg Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu 
            100                 105                 110         


Val Thr Val Ser Ser 
        115         


<210>  14
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  VH1.8/VL1.2 light chain variable (VL) region

<400>  14

Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 
1               5                   10                  15      


Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Gly Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Leu Leu Ile Tyr Lys Gly Ser Asn Arg Phe Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Phe Gln Ala 
                85                  90                  95      


Ser Gln Val Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  15
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  D6 heavy chain variable (VH) region

<400>  15

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 
1               5                   10                  15      


Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Asn Tyr 
            20                  25                  30          


Asn Ile His Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Thr Ile Tyr Pro Gly Asn Ser Asp Thr Ser Tyr Asn Pro Ser Phe 
    50                  55                  60                  


Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Gly Gly Val Arg Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu 
            100                 105                 110         


Val Thr Val Ser Ser 
        115         


<210>  16
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  D6 light chain variable (VL) region

<400>  16

Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 
1               5                   10                  15      


Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Gly Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Leu Leu Ile Tyr Lys Gly Ser Asn Arg Phe Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala 
                85                  90                  95      


Ser Gln Val Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  17
<211>  327
<212>  PRT
<213>  Homo sapiens

<400>  17

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg 
1               5                   10                  15      


Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 
            20                  25                  30          


Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 
        35                  40                  45              


Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 
    50                  55                  60                  


Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr 
65                  70                  75                  80  


Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys 
                85                  90                  95      


Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Ser Cys Pro Ala Pro 
            100                 105                 110         


Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 
        115                 120                 125             


Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 
    130                 135                 140                 


Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp 
145                 150                 155                 160 


Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe 
                165                 170                 175     


Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp 
            180                 185                 190         


Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu 
        195                 200                 205             


Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 
    210                 215                 220                 


Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys 
225                 230                 235                 240 


Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 
                245                 250                 255     


Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 
            260                 265                 270         


Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 
        275                 280                 285             


Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser 
    290                 295                 300                 


Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser 
305                 310                 315                 320 


Leu Ser Leu Ser Leu Gly Lys 
                325         


<210>  18
<211>  327
<212>  PRT
<213>  Homo sapiens

<400>  18

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg 
1               5                   10                  15      


Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 
            20                  25                  30          


Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 
        35                  40                  45              


Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 
    50                  55                  60                  


Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr 
65                  70                  75                  80  


Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys 
                85                  90                  95      


Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro 
            100                 105                 110         


Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 
        115                 120                 125             


Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 
    130                 135                 140                 


Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp 
145                 150                 155                 160 


Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe 
                165                 170                 175     


Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp 
            180                 185                 190         


Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu 
        195                 200                 205             


Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 
    210                 215                 220                 


Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys 
225                 230                 235                 240 


Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 
                245                 250                 255     


Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 
            260                 265                 270         


Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 
        275                 280                 285             


Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser 
    290                 295                 300                 


Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser 
305                 310                 315                 320 


Leu Ser Leu Ser Leu Gly Lys 
                325         


<210>  19
<211>  330
<212>  PRT
<213>  Homo sapiens

<400>  19

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 
1               5                   10                  15      


Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 
            20                  25                  30          


Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 
        35                  40                  45              


Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 
    50                  55                  60                  


Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 
65                  70                  75                  80  


Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 
                85                  90                  95      


Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys 
            100                 105                 110         


Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 
        115                 120                 125             


Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 
    130                 135                 140                 


Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp 
145                 150                 155                 160 


Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 
                165                 170                 175     


Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 
            180                 185                 190         


His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 
        195                 200                 205             


Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 
    210                 215                 220                 


Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu 
225                 230                 235                 240 


Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 
                245                 250                 255     


Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 
            260                 265                 270         


Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 
        275                 280                 285             


Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 
    290                 295                 300                 


Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 
305                 310                 315                 320 


Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 
                325                 330 


<210>  20
<211>  330
<212>  PRT
<213>  Homo sapiens

<400>  20

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 
1               5                   10                  15      


Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 
            20                  25                  30          


Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 
        35                  40                  45              


Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 
    50                  55                  60                  


Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 
65                  70                  75                  80  


Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 
                85                  90                  95      


Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys 
            100                 105                 110         


Pro Ala Pro Glu Ala Ala Gly Ala Pro Ser Val Phe Leu Phe Pro Pro 
        115                 120                 125             


Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 
    130                 135                 140                 


Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp 
145                 150                 155                 160 


Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 
                165                 170                 175     


Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 
            180                 185                 190         


His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 
        195                 200                 205             


Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 
    210                 215                 220                 


Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu 
225                 230                 235                 240 


Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 
                245                 250                 255     


Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 
            260                 265                 270         


Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 
        275                 280                 285             


Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 
    290                 295                 300                 


Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 
305                 310                 315                 320 


Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 
                325                 330 


<210>  21
<211>  326
<212>  PRT
<213>  Homo sapiens

<400>  21

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg 
1               5                   10                  15      


Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 
            20                  25                  30          


Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 
        35                  40                  45              


Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 
    50                  55                  60                  


Leu Ser Ser Val Val Thr Val Pro Ser Ser Asn Phe Gly Thr Gln Thr 
65                  70                  75                  80  


Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys 
                85                  90                  95      


Thr Val Glu Arg Lys Cys Cys Val Glu Cys Pro Pro Cys Pro Ala Pro 
            100                 105                 110         


Pro Val Ala Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp 
        115                 120                 125             


Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp 
    130                 135                 140                 


Val Ser His Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly 
145                 150                 155                 160 


Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn 
                165                 170                 175     


Ser Thr Phe Arg Val Val Ser Val Leu Thr Val Val His Gln Asp Trp 
            180                 185                 190         


Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro 
        195                 200                 205             


Ala Pro Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly Gln Pro Arg Glu 
    210                 215                 220                 


Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn 
225                 230                 235                 240 


Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile 
                245                 250                 255     


Ser Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr 
            260                 265                 270         


Thr Pro Pro Met Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys 
        275                 280                 285             


Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys 
    290                 295                 300                 


Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu 
305                 310                 315                 320 


Ser Leu Ser Pro Gly Lys 
                325     


<210>  22
<211>  330
<212>  PRT
<213>  Homo sapiens

<400>  22

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 
1               5                   10                  15      


Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 
            20                  25                  30          


Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 
        35                  40                  45              


Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 
    50                  55                  60                  


Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 
65                  70                  75                  80  


Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 
                85                  90                  95      


Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys 
            100                 105                 110         


Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 
        115                 120                 125             


Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 
    130                 135                 140                 


Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp 
145                 150                 155                 160 


Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 
                165                 170                 175     


Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 
            180                 185                 190         


His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 
        195                 200                 205             


Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 
    210                 215                 220                 


Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu 
225                 230                 235                 240 


Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 
                245                 250                 255     


Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 
            260                 265                 270         


Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 
        275                 280                 285             


Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 
    290                 295                 300                 


Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 
305                 310                 315                 320 


Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 
                325                 330 


<210>  23
<211>  329
<212>  PRT
<213>  Homo sapiens

<400>  23

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 
1               5                   10                  15      


Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 
            20                  25                  30          


Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 
        35                  40                  45              


Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 
    50                  55                  60                  


Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 
65                  70                  75                  80  


Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 
                85                  90                  95      


Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys 
            100                 105                 110         


Pro Ala Pro Glu Ala Ala Gly Ala Pro Ser Val Phe Leu Phe Pro Pro 
        115                 120                 125             


Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 
    130                 135                 140                 


Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp 
145                 150                 155                 160 


Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 
                165                 170                 175     


Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 
            180                 185                 190         


His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 
        195                 200                 205             


Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 
    210                 215                 220                 


Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu 
225                 230                 235                 240 


Met Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro 
                245                 250                 255     


Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn 
            260                 265                 270         


Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu 
        275                 280                 285             


Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val 
    290                 295                 300                 


Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln 
305                 310                 315                 320 


Lys Ser Leu Ser Leu Ser Pro Gly Lys 
                325                 


<210>  24
<211>  323
<212>  PRT
<213>  Homo sapiens

<400>  24

Met Trp Pro Leu Val Ala Ala Leu Leu Leu Gly Ser Ala Cys Cys Gly 
1               5                   10                  15      


Ser Ala Gln Leu Leu Phe Asn Lys Thr Lys Ser Val Glu Phe Thr Phe 
            20                  25                  30          


Cys Asn Asp Thr Val Val Ile Pro Cys Phe Val Thr Asn Met Glu Ala 
        35                  40                  45              


Gln Asn Thr Thr Glu Val Tyr Val Lys Trp Lys Phe Lys Gly Arg Asp 
    50                  55                  60                  


Ile Tyr Thr Phe Asp Gly Ala Leu Asn Lys Ser Thr Val Pro Thr Asp 
65                  70                  75                  80  


Phe Ser Ser Ala Lys Ile Glu Val Ser Gln Leu Leu Lys Gly Asp Ala 
                85                  90                  95      


Ser Leu Lys Met Asp Lys Ser Asp Ala Val Ser His Thr Gly Asn Tyr 
            100                 105                 110         


Thr Cys Glu Val Thr Glu Leu Thr Arg Glu Gly Glu Thr Ile Ile Glu 
        115                 120                 125             


Leu Lys Tyr Arg Val Val Ser Trp Phe Ser Pro Asn Glu Asn Ile Leu 
    130                 135                 140                 


Ile Val Ile Phe Pro Ile Phe Ala Ile Leu Leu Phe Trp Gly Gln Phe 
145                 150                 155                 160 


Gly Ile Lys Thr Leu Lys Tyr Arg Ser Gly Gly Met Asp Glu Lys Thr 
                165                 170                 175     


Ile Ala Leu Leu Val Ala Gly Leu Val Ile Thr Val Ile Val Ile Val 
            180                 185                 190         


Gly Ala Ile Leu Phe Val Pro Gly Glu Tyr Ser Leu Lys Asn Ala Thr 
        195                 200                 205             


Gly Leu Gly Leu Ile Val Thr Ser Thr Gly Ile Leu Ile Leu Leu His 
    210                 215                 220                 


Tyr Tyr Val Phe Ser Thr Ala Ile Gly Leu Thr Ser Phe Val Ile Ala 
225                 230                 235                 240 


Ile Leu Val Ile Gln Val Ile Ala Tyr Ile Leu Ala Val Val Gly Leu 
                245                 250                 255     


Ser Leu Cys Ile Ala Ala Cys Ile Pro Met His Gly Pro Leu Leu Ile 
            260                 265                 270         


Ser Gly Leu Ser Ile Leu Ala Leu Ala Gln Leu Leu Gly Leu Val Tyr 
        275                 280                 285             


Met Lys Phe Val Ala Ser Asn Gln Lys Thr Ile Gln Pro Pro Arg Lys 
    290                 295                 300                 


Ala Val Glu Glu Pro Leu Asn Ala Phe Lys Glu Ser Lys Gly Met Met 
305                 310                 315                 320 


Asn Asp Glu 
            


<210>  25
<211>  323
<212>  PRT
<213>  Macaca fascicularis

<400>  25

Met Trp Pro Leu Val Ala Ala Leu Leu Leu Gly Ser Ala Cys Cys Gly 
1               5                   10                  15      


Ser Ala Gln Leu Leu Phe Asn Lys Thr Lys Ser Val Glu Phe Thr Phe 
            20                  25                  30          


Cys Asn Asp Thr Val Val Ile Pro Cys Phe Val Thr Asn Met Glu Ala 
        35                  40                  45              


Gln Asn Thr Thr Glu Val Tyr Val Lys Trp Lys Phe Lys Gly Arg Asp 
    50                  55                  60                  


Ile Tyr Thr Phe Asp Gly Ala Leu Asn Lys Ser Thr Ala Pro Ala Asn 
65                  70                  75                  80  


Phe Ser Ser Ala Lys Ile Glu Val Ser Gln Leu Leu Lys Gly Asp Ala 
                85                  90                  95      


Ser Leu Lys Met Asp Lys Ser Asp Ala Val Ser His Thr Gly Asn Tyr 
            100                 105                 110         


Thr Cys Glu Val Thr Glu Leu Thr Arg Glu Gly Glu Thr Ile Ile Glu 
        115                 120                 125             


Leu Lys Tyr Arg Val Val Ser Trp Phe Ser Pro Asn Glu Asn Ile Leu 
    130                 135                 140                 


Ile Val Ile Phe Pro Ile Phe Ala Ile Leu Leu Phe Trp Gly Gln Phe 
145                 150                 155                 160 


Gly Ile Lys Thr Leu Lys Tyr Arg Ser Gly Gly Met Asp Glu Lys Thr 
                165                 170                 175     


Ile Ala Leu Leu Val Ala Gly Leu Met Ile Thr Val Ile Val Ile Val 
            180                 185                 190         


Gly Ala Ile Leu Phe Val Pro Gly Glu Tyr Ser Leu Lys Asn Ala Thr 
        195                 200                 205             


Gly Leu Gly Leu Ile Val Thr Ser Thr Gly Ile Leu Ile Leu Leu His 
    210                 215                 220                 


Tyr Tyr Val Phe Ser Thr Ala Ile Gly Leu Thr Ser Phe Val Ile Ala 
225                 230                 235                 240 


Ile Leu Val Ile Gln Val Ile Ala Tyr Ile Leu Ala Val Val Gly Leu 
                245                 250                 255     


Ser Leu Cys Ile Ala Ala Cys Ile Pro Met His Gly Pro Leu Leu Ile 
            260                 265                 270         


Ser Gly Leu Ser Ile Leu Ala Leu Ala Gln Leu Leu Gly Leu Val Tyr 
        275                 280                 285             


Met Lys Phe Val Ala Ser Asn Gln Lys Thr Ile Gln Pro Pro Arg Lys 
    290                 295                 300                 


Ala Val Glu Glu Pro Leu Asn Ala Phe Lys Glu Ser Lys Gly Met Met 
305                 310                 315                 320 


Asn Asp Glu 
            


<210>  26
<211>  5
<212>  PRT
<213>  Homo sapiens

<400>  26

Arg Asp Glu Leu Thr 
1               5   


<210>  27
<211>  4
<212>  PRT
<213>  Homo sapiens

<400>  27

Arg Glu Glu Met 
1               


<210>  28
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR1

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa can be Asn or a conservative substitution of Asn

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa can be Asn or a conservative substitution of Asn

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa can be Met or a conservative substitution of Met

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa can be His or any amino acid

<400>  28

Gly Tyr Ser Phe Thr Xaa Tyr Xaa Xaa Xaa 
1               5                   10  


<210>  29
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa can be Met or a conservative substitution of Met

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa can be Thr or any amino acid

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa can be Asn or any amino acid

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa can be Asp or any amino acid

<220>
<221>  misc_feature
<222>  (12)..(12)
<223>  Xaa can be Ser or any amino acid

<220>
<221>  misc_feature
<222>  (14)..(14)
<223>  Xaa can be Asn or any amino acid

<220>
<221>  misc_feature
<222>  (15)..(15)
<223>  Xaa can be Gln or any amino acid

<220>
<221>  misc_feature
<222>  (16)..(16)
<223>  Xaa can be Lys or any amino acid

<220>
<221>  misc_feature
<222>  (18)..(18)
<223>  Xaa can be Gln or Lys

<220>
<221>  misc_feature
<222>  (19)..(19)
<223>  Xaa can be Gly or Asp

<400>  29

Xaa Gly Xaa Ile Tyr Pro Gly Xaa Xaa Asp Thr Xaa Tyr Xaa Xaa Xaa 
1               5                   10                  15      


Phe Xaa Xaa 
            


<210>  30
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR3

<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa can be Gly or any amino acid

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa can be Tyr or any amino acid

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa can be Ala or any amino acid

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa can be Met or any amino acid

<400>  30

Xaa Gly Xaa Arg Xaa Xaa Asp Tyr 
1               5               


<210>  31
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR1

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa can be Asn or any amino acid

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa can be Asn or any amino acid

<400>  31

Gly Tyr Thr Phe Thr Xaa Tyr Xaa Met His 
1               5                   10  


<210>  32
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa can be Asp or any amino acid 

<220>
<221>  misc_feature
<222>  (12)..(12)
<223>  Xaa can be Ser or any amino acid

<220>
<221>  misc_feature
<222>  (14)..(14)
<223>  Xaa can be Asn or any amino acid

<400>  32

Met Gly Thr Ile Tyr Pro Gly Asn Asp Xaa Thr Xaa Tyr Xaa Gln Lys 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  33
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  5F9G4 murine/humanized antibody HCDR1

<400>  33

Gly Tyr Thr Phe Thr Asn Tyr Asn Met His 
1               5                   10  


<210>  34
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  5F9G4 murine/humanized antibody HCDR2

<400>  34

Met Gly Thr Ile Tyr Pro Gly Asn Asp Asp Thr Ser Tyr Asn Gln Lys 
1               5                   10                  15      


Phe Lys Asp 
            


<210>  35
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  5F9G4 murine/humanized antibody HCDR3

<400>  35

Gly Gly Tyr Arg Ala Met Asp Tyr 
1               5               


<210>  36
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR1

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa can be Ile or a conservative substitution of Ile

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa can be Val or a conservative substitution of Val

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa can be Tyr or a conservative substitution of Tyr

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa can be Asn or any amino acid

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa can be Gly or any amino acid

<220>
<221>  misc_feature
<222>  (12)..(12)
<223>  Xaa can be Asn or any amino acid

<220>
<221>  misc_feature
<222>  (13)..(13)
<223>  Xaa can be Thr or any amino acid

<220>
<221>  misc_feature
<222>  (16)..(16)
<223>  Xaa can be Gly or any amino acid

<400>  36

Arg Ser Ser Gln Ser Xaa Xaa Xaa Ser Xaa Xaa Xaa Xaa Tyr Leu Xaa 
1               5                   10                  15      


<210>  37
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR2

<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa can be Val or any amino acid

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa can be Phe or any amino acid 

<400>  37

Lys Xaa Ser Asn Arg Xaa Ser 
1               5           


<210>  38
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR3

<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa can be Phe or any amino acid

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa can be Gly or any amino acid

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa can be Ser or any amino acid

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa can be His or any amino acid

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa can be Val or any amino acid

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa can be Thr or any amino acid

<400>  38

Xaa Gln Xaa Xaa Xaa Xaa Pro Tyr Xaa 
1               5                   


<210>  39
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  5F9G4 murine/humanized antibody LCDR1

<400>  39

Arg Ser Ser Gln Ser Ile Val Tyr Ser Asn Gly Asn Thr Tyr Leu Gly 
1               5                   10                  15      


<210>  40
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  5F9G4 murine/humanized antibody LCDR2

<400>  40

Lys Val Ser Asn Arg Phe Ser 
1               5           


<210>  41
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  5F9G4 murine/humanized antibody LCDR3

<400>  41

Phe Gln Gly Ser His Val Pro Tyr Thr 
1               5                   


<210>  42
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR1


<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa can be Ser or a conservative substitution of Ser

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa can be Asn or a conservative substitution of Asn

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa can be Asn or any other amino acid

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa can be Met or a conservative substitution of Met

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa can be His or any other amino acid

<400>  42

Gly Tyr Xaa Phe Thr Xaa Tyr Xaa Xaa Xaa 
1               5                   10  


<210>  43
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa can be Met or a conservative substitution of Met

<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa can be Gly or a conservative substitution of Gly

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa can be Thr or any other amino acid

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa can be Asn or a conservative substitution of Asn

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa can be Asp or any other amino acid

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa can be Asp or any other amino acid

<220>
<221>  misc_feature
<222>  (12)..(12)
<223>  Xaa can be Ser or any other amino acid

<220>
<221>  misc_feature
<222>  (14)..(14)
<223>  Xaa can be Asn or any other amino acid

<220>
<221>  misc_feature
<222>  (15)..(15)
<223>  Xaa can be Gln or any other amino acid

<220>
<221>  misc_feature
<222>  (16)..(16)
<223>  Xaa can be Lys or any other amino acid

<400>  43

Xaa Xaa Xaa Ile Tyr Pro Gly Xaa Xaa Xaa Thr Xaa Tyr Xaa Xaa Xaa 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  44
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR3


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa can be Gly or any other amino acid

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa can be Tyr or any other amino acid

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa can be Ala or any other amino acid

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa can be Met or any other amino acid

<400>  44

Xaa Gly Xaa Arg Xaa Xaa Asp Tyr 
1               5               


<210>  45
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR1


<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa can be Ile or a conservative substitution of Ile

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa can be Val or a conservative substitution of Val

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa can be Tyr or a conservative substitution of Tyr

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa can be Asn or any other amino acid

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa can be Gly or any other amino acid

<220>
<221>  misc_feature
<222>  (12)..(12)
<223>  Xaa can be Asn or any other amino acid

<220>
<221>  misc_feature
<222>  (13)..(13)
<223>  Xaa can be Thr or any other amino acid

<220>
<221>  misc_feature
<222>  (16)..(16)
<223>  Xaa can be Gly or any other amino acid

<400>  45

Arg Ser Ser Gln Ser Xaa Xaa Xaa Ser Xaa Xaa Xaa Xaa Tyr Leu Xaa 
1               5                   10                  15      


<210>  46
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR2


<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa can be Val or any other amino acid

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa can be Phe or any other amino acid

<400>  46

Lys Xaa Ser Asn Arg Xaa Ser 
1               5           


<210>  47
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR3


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa can be Phe or any other amino acid

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa can be Gly or any other amino acid

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa can be Ser or any other amino acid

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa can be His or any other amino acid

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa can be Val or any other amino acid

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa can be Thr or any other amino acid

<400>  47

Xaa Gln Xaa Xaa Xaa Xaa Pro Tyr Xaa 
1               5                   


<210>  48
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR1

<400>  48

Gly Tyr Thr Phe Thr Asn Tyr Ala Met His 
1               5                   10  


<210>  49
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  49

Met Gly Thr Ile Tyr Pro Gly Asn Asp Asp Thr Lys Tyr Asn Gln Lys 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  50
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR3

<400>  50

Gly Gly Phe Arg Ala Met Asp Tyr 
1               5               


<210>  51
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR1

<400>  51

Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Asn Thr Tyr Leu Gly 
1               5                   10                  15      


<210>  52
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR2

<400>  52

Lys Gly Ser Asn Arg Phe Ser 
1               5           


<210>  53
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR3

<400>  53

Phe Gln Ala Ser His Val Pro Tyr Thr 
1               5                   


<210>  54
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR3

<400>  54

Phe Gln Ala Ser Gln Val Pro Tyr Thr 
1               5                   


<210>  55
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR1

<400>  55

Arg Ser Ser Gln Ser Leu Leu His Ser Asn Ala Asn Thr Tyr Leu Gly 
1               5                   10                  15      


<210>  56
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR1

<400>  56

Arg Ser Ser Gln Ser Leu Leu His Ser Asn Ala Tyr Asn Tyr Leu Gly 
1               5                   10                  15      


<210>  57
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR1

<400>  57

Gly Tyr Ser Phe Thr Asn Tyr Asn Ile His 
1               5                   10  


<210>  58
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  58

Met Gly Thr Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Asn Pro Lys 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  59
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR3

<400>  59

Gly Gly Tyr Arg Ala Glu Asp Tyr 
1               5               


<210>  60
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR3

<400>  60

Met Gln Gly Ser His Val Pro Tyr 
1               5               


<210>  61
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  61

Met Gly Thr Ile Tyr Pro Gly Asn Ser Asp Thr Ser Tyr Asn Pro Ser 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  62
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR3

<400>  62

Gly Gly Val Arg Ala Met Asp Tyr 
1               5               


<210>  63
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR3

<400>  63

Met Gln Ala Ser Gln Val Pro Tyr Thr 
1               5                   


<210>  64
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion VH CDR

<400>  64

Gly Tyr Ser Phe Thr Asn Tyr Asn Met His 
1               5                   10  


<210>  65
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion VH CDR

<400>  65

Met Gly Thr Ile Tyr Pro Gly Asn Asp Asp Thr Ser Tyr Asn Gln Lys 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  66
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion VH CDR

<400>  66

Gly Gly Tyr Arg Ala Met Asp Tyr 
1               5               


<210>  67
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion VL CDR

<400>  67

Arg Ser Ser Gly Ser Ile Val Tyr Ser Asn Gly Asn Thr Tyr Leu Gly 
1               5                   10                  15      


<210>  68
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion VL CDR

<400>  68

Lys Val Ser Asn Arg Phe Ser 
1               5           


<210>  69
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion VL CDR

<400>  69

Phe Gln Gly Ser His Val Pro Tyr Thr 
1               5                   


<210>  70
<211>  40
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR1

<400>  70

Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 
1               5                   10                  15      


Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val Tyr Ser 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Gly Trp 
        35                  40  


<210>  71
<211>  40
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR1

<400>  71

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 
            20                  25                  30          


Asn Met His Trp Val Arg Gln Ala 
        35                  40  


<210>  72
<211>  37
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR3

<400>  72

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
1               5                   10                  15      


Ala Arg Gly Gly Tyr Arg Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu 
            20                  25                  30          


Val Thr Val Ser Ser 
        35          


<210>  73
<211>  77
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR2

<400>  73

Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 
1               5                   10                  15      


Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Gly Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Leu Leu Ile Tyr Lys Gly Ser Asn Arg Phe Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr 
65                  70                  75          


<210>  74
<211>  35
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR3

<400>  74

Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys 
1               5                   10                  15      


Phe Gln Ala Ser His Val Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu 
            20                  25                  30          


Glu Ile Lys 
        35  


<210>  75
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa can be Met or a conservative substitution of Met

<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa can be Gly or a conservative substitution of Gly

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa can be Thr or any other amino acid

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa can be Asn or any other amino acid

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa can be Asp or any other amino acid

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa can be Asp or any other amino acid

<220>
<221>  misc_feature
<222>  (12)..(12)
<223>  Xaa can be Ser or any other amino acid

<220>
<221>  misc_feature
<222>  (14)..(14)
<223>  Xaa can be Asn or any other amino acid

<220>
<221>  misc_feature
<222>  (15)..(15)
<223>  Xaa can be Gln or any other amino acid

<220>
<221>  misc_feature
<222>  (16)..(16)
<223>  Xaa can be Lys or any other amino acid

<400>  75

Xaa Xaa Xaa Ile Tyr Pro Gly Xaa Xaa Xaa Thr Xaa Tyr Xaa Xaa Xaa 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  76
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR1


<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa can be Thr or Ser

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa can be Asn, Ser or Asp

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa can be Asn, Ser or Ala

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa can be Met or Ile

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa can be His or Gly

<400>  76

Gly Tyr Xaa Phe Thr Xaa Tyr Xaa Xaa Xaa 
1               5                   10  


<210>  77
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa can be Met, Ile or Val

<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa can be Gly, Ala or Ser

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa can be Thr or Ile

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa can be Asn or Asp

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa can be Asp or Ser

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa can be Asp or Asn

<220>
<221>  misc_feature
<222>  (12)..(12)
<223>  Xaa can be Ser, Lys or Arg

<220>
<221>  misc_feature
<222>  (14)..(14)
<223>  Xaa can be Asn, Ser or His

<220>
<221>  misc_feature
<222>  (15)..(15)
<223>  Xaa can be Gln, Pro or His

<220>
<221>  misc_feature
<222>  (16)..(16)
<223>  Xaa can be Lys or Ser

<220>
<221>  misc_feature
<222>  (18)..(18)
<223>  Xaa can be Lys or Gln

<220>
<221>  misc_feature
<222>  (19)..(19)
<223>  Xaa can be Asp or Gly

<400>  77

Xaa Xaa Xaa Ile Tyr Pro Gly Xaa Xaa Xaa Thr Xaa Tyr Xaa Xaa Xaa 
1               5                   10                  15      


Phe Xaa Xaa 
            


<210>  78
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR3


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa can be Gly or Gln

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa can be Tyr, Ala, Cys, Asp, Glu, Phe, Gly, His, Ile, 
       Lys, Leu, Met, Asn, Gln, Arg, Ser, Thr, Val or Trp

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa can be Ala, Ile, Thr, Val or Trp

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa can be Met, Ala, Glu, Lys, Leu, Pro, Gln, Arg, Ser, 
       Thr, Val or Trp

<400>  78

Xaa Gly Xaa Arg Xaa Xaa Asp Tyr 
1               5               


<210>  79
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR1


<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa can be Thr or Ser

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa can be Asn or Asp

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa can be Asn or Ala

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa can be Met or Ile

<400>  79

Gly Tyr Xaa Phe Thr Xaa Tyr Xaa Xaa His 
1               5                   10  


<210>  80
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2


<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa can be Asn or Asp

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa can be Asp or Ser

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa can be Asp or Asn

<220>
<221>  misc_feature
<222>  (12)..(12)
<223>  Xaa can be Ser, Lys or Arg

<220>
<221>  misc_feature
<222>  (14)..(14)
<223>  Xaa can be Asn or Ser

<220>
<221>  misc_feature
<222>  (15)..(15)
<223>  Xaa can be Gln, Pro or His

<220>
<221>  misc_feature
<222>  (16)..(16)
<223>  Xaa can be Lys or Ser

<400>  80

Met Gly Thr Ile Tyr Pro Gly Xaa Xaa Xaa Thr Xaa Tyr Xaa Xaa Xaa 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  81
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR3


<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa can be Tyr, Glu, Phe, Ile, Lys, Asn or Val

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa can be Met, Glu or Gln

<400>  81

Gly Gly Xaa Arg Ala Xaa Asp Tyr 
1               5               


<210>  82
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR1


<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa can be Val or Leu

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa can be Tyr or His

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa can be Asn, Gly, Ser or Lys

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa can be Gly, Ala or Tyr

<220>
<221>  misc_feature
<222>  (12)..(12)
<223>  Xaa can be Asn or Tyr

<220>
<221>  misc_feature
<222>  (13)..(13)
<223>  Xaa can be Thr or Asn

<220>
<221>  misc_feature
<222>  (16)..(16)
<223>  Xaa can be Gly or Asp

<400>  82

Arg Ser Ser Gln Ser Leu Xaa Xaa Ser Xaa Xaa Xaa Xaa Tyr Leu Xaa 
1               5                   10                  15      


<210>  83
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR2


<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa can be Phe or Ala

<400>  83

Lys Gly Ser Asn Arg Xaa Ser 
1               5           


<210>  84
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR3


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa can be Phe or Met

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa can be Gly or Ala

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa can be His or Gln

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa can be Thr or Ile

<400>  84

Xaa Gln Xaa Ser Xaa Val Pro Tyr Xaa 
1               5                   


<210>  85
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR1


<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa can be Asn or Lys

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa can be Gly, Ala or Tyr 

<220>
<221>  misc_feature
<222>  (12)..(12)
<223>  Xaa can be Asn, Gln or Tyr

<220>
<221>  misc_feature
<222>  (13)..(13)
<223>  Xaa can be Thr or Asn

<400>  85

Arg Ser Ser Gln Ser Leu Leu His Ser Xaa Xaa Xaa Xaa Tyr Leu Gly 
1               5                   10                  15      


<210>  86
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR2


<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa can be Val or Gly

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa can be Phe, Ala or Ser

<400>  86

Lys Xaa Ser Asn Arg Xaa Ser 
1               5           


<210>  87
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR3


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa can be Phe, Leu or Met

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa can be Gly or Ala

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa can be Ser, Thr, Leu or Met

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa can be His, Gln or Arg

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa can be Val, Ile or Thr

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa can be Thr or Ile

<400>  87

Xaa Gln Xaa Xaa Xaa Xaa Pro Tyr Xaa 
1               5                   


<210>  88
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR1

<400>  88

Gly Tyr Thr Phe Thr Asp Tyr Asn Met His 
1               5                   10  


<210>  89
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR1

<400>  89

Gly Tyr Thr Phe Thr Asn Tyr Asn Ile His 
1               5                   10  


<210>  90
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  90

Met Gly Thr Ile Tyr Pro Gly Asn Asp Asp Thr Ser Tyr Ser Gln Lys 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  91
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  91

Met Gly Thr Ile Tyr Pro Gly Asn Asp Asp Thr Lys Tyr Ser Gln Lys 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  92
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  92

Met Gly Thr Ile Tyr Pro Gly Asn Ser Asp Thr Ser Tyr Asn Pro Lys 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  93
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR3

<400>  93

Gly Gly Lys Arg Ala Met Asp Tyr 
1               5               


<210>  94
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  94

Met Gly Thr Ile Tyr Pro Gly Asp Ser Asp Thr Ser Tyr Asn Pro Lys 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  95
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR3

<400>  95

Gly Gly Tyr Arg Ala Gln Asp Tyr 
1               5               


<210>  96
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR3

<400>  96

Met Gln Ala Ser His Val Pro Tyr Thr 
1               5                   


<210>  97
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR3

<400>  97

Met Gln Gly Ser His Val Pro Tyr Thr 
1               5                   


<210>  98
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  98

Met Gly Thr Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Asn Gln Lys 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  99
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR3

<400>  99

Gly Gly Ile Arg Ala Met Asp Tyr 
1               5               


<210>  100
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR3

<400>  100

Phe Gln Gly Ser His Val Pro Tyr Ile 
1               5                   


<210>  101
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  101

Met Gly Thr Ile Tyr Pro Gly Asn Ser Asp Thr Arg Tyr Asn Pro Lys 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  102
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  human germline peptide sequence with high MHC class II binding affinity in the HCDR2

<400>  102

Phe Gln Gly Gln Val Thr Ile Ser Ala 
1               5                   


<210>  103
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  human germline peptide sequence with high MHC class II binding affinity in the HCDR2

<400>  103

Phe Gln Gly Arg Val Thr Ile Thr Ala 
1               5                   


<210>  104
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR1


<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa can be Asn or a conservative substitution of Asn

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa can be Asn or any other amino acid

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa can be Met or a conservative substitution of Met

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa can be His or any other amino acid

<400>  104

Gly Tyr Thr Phe Thr Xaa Tyr Xaa Xaa Xaa 
1               5                   10  


<210>  105
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2


<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa can be Thr or any other amino acid

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa can be Asn or a conservative substitution of Asn

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa can be Asp or any other amino acid

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa can be Asp or any other amino acid

<220>
<221>  misc_feature
<222>  (12)..(12)
<223>  Xaa can be Ser or any other amino acid

<220>
<221>  misc_feature
<222>  (14)..(14)
<223>  Xaa can be Asn or any other amino acid

<220>
<221>  misc_feature
<222>  (15)..(15)
<223>  Xaa can be Gln or any other amino acid

<220>
<221>  misc_feature
<222>  (16)..(16)
<223>  Xaa can be Lys or any other amino acid

<400>  105

Met Gly Xaa Ile Tyr Pro Gly Xaa Xaa Xaa Thr Xaa Tyr Xaa Xaa Xaa 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  106
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  TCED+ peptide

<400>  106

Ile Val Tyr Ser Asn Gly Asn Thr Tyr 
1               5                   


<210>  107
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  HAF and TCED+ peptide

<400>  107

Tyr Asn Met His Trp Val Arg Gln Ala 
1               5                   


<210>  108
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  TCED+ peptide

<400>  108

Tyr Ala Met His Trp Val Arg Gln Ala 
1               5                   


<210>  109
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  TCED+ peptide

<400>  109

Tyr Asn Ile His Trp Val Arg Gln Ala 
1               5                   


<210>  110
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  TCED+ peptide

<400>  110

Tyr Arg Ala Met Asp Tyr Trp Gly Gln 
1               5                   


<210>  111
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  TCED+ peptide

<400>  111

Tyr Arg Ala Glu Asp Tyr Trp Gly Gln 
1               5                   


<210>  112
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  HAF peptide

<400>  112

Leu Ile Tyr Lys Gly Ser Asn Arg Phe 
1               5                   


<210>  113
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  HAF peptide

<400>  113

Val Gly Val Tyr Tyr Cys Phe Gln Ala 
1               5                   


<210>  114
<211>  10
<212>  PRT
<213>  Mus musculus

<400>  114

Gly Tyr Thr Phe Thr Asn Tyr Asn Met His 
1               5                   10  


<210>  115
<211>  5
<212>  PRT
<213>  Mus musculus

<400>  115

Asn Tyr Asn Met His 
1               5   


<210>  116
<211>  7
<212>  PRT
<213>  Mus musculus

<400>  116

Gly Tyr Thr Phe Thr Asn Tyr 
1               5           


<210>  117
<211>  8
<212>  PRT
<213>  Mus musculus

<400>  117

Gly Tyr Thr Phe Thr Asn Tyr Asn 
1               5               


<210>  118
<211>  6
<212>  PRT
<213>  Mus musculus

<400>  118

Thr Asn Tyr Asn Met His 
1               5       


<210>  119
<211>  19
<212>  PRT
<213>  Mus musculus

<400>  119

Met Gly Thr Ile Tyr Pro Gly Asn Asp Asp Thr Ser Tyr Asn Gln Lys 
1               5                   10                  15      


Phe Lys Asp 
            


<210>  120
<211>  17
<212>  PRT
<213>  Mus musculus

<400>  120

Thr Ile Tyr Pro Gly Asn Asp Asp Thr Ser Tyr Asn Gln Lys Phe Lys 
1               5                   10                  15      


Asp 
    


<210>  121
<211>  6
<212>  PRT
<213>  Mus musculus

<400>  121

Tyr Pro Gly Asn Asp Asp 
1               5       


<210>  122
<211>  8
<212>  PRT
<213>  Mus musculus

<400>  122

Ile Tyr Pro Gly Asn Asp Asp Thr 
1               5               


<210>  123
<211>  16
<212>  PRT
<213>  Mus musculus

<400>  123

Ile Tyr Pro Gly Asn Asp Asp Thr Ser Tyr Asn Gln Lys Phe Lys Asp 
1               5                   10                  15      


<210>  124
<211>  10
<212>  PRT
<213>  Mus musculus

<400>  124

Thr Ile Tyr Pro Gly Asn Asp Asp Thr Ser 
1               5                   10  


<210>  125
<211>  12
<212>  PRT
<213>  Mus musculus

<400>  125

Met Gly Thr Ile Tyr Pro Gly Asn Asp Asp Thr Ser 
1               5                   10          


<210>  126
<211>  8
<212>  PRT
<213>  Mus musculus

<400>  126

Gly Gly Tyr Arg Ala Met Asp Tyr 
1               5               


<210>  127
<211>  10
<212>  PRT
<213>  Mus musculus

<400>  127

Ala Arg Gly Gly Tyr Arg Ala Met Asp Tyr 
1               5                   10  


<210>  128
<211>  7
<212>  PRT
<213>  Mus musculus

<400>  128

Gly Gly Tyr Arg Ala Met Asp 
1               5           


<210>  129
<211>  9
<212>  PRT
<213>  Mus musculus

<400>  129

Ala Arg Gly Gly Tyr Arg Ala Met Asp 
1               5                   


<210>  130
<211>  16
<212>  PRT
<213>  Mus musculus

<400>  130

Arg Ser Ser Gln Ser Ile Val Tyr Ser Asn Gly Asn Thr Tyr Leu Gly 
1               5                   10                  15      


<210>  131
<211>  11
<212>  PRT
<213>  Mus musculus

<400>  131

Gln Ser Ile Val Tyr Ser Asn Gly Asn Thr Tyr 
1               5                   10      


<210>  132
<211>  13
<212>  PRT
<213>  Mus musculus

<400>  132

Ser Ser Gln Ser Ile Val Tyr Ser Asn Gly Asn Thr Tyr 
1               5                   10              


<210>  133
<211>  12
<212>  PRT
<213>  Mus musculus

<400>  133

Val Tyr Ser Asn Gly Asn Thr Tyr Leu Gly Trp Tyr 
1               5                   10          


<210>  134
<211>  7
<212>  PRT
<213>  Mus musculus

<400>  134

Lys Val Ser Asn Arg Phe Ser 
1               5           


<210>  135
<211>  10
<212>  PRT
<213>  Mus musculus

<400>  135

Ala Leu Ile Tyr Lys Val Ser Asn Arg Phe 
1               5                   10  


<210>  136
<211>  9
<212>  PRT
<213>  Mus musculus

<400>  136

Phe Gln Gly Ser His Val Pro Tyr Thr 
1               5                   


<210>  137
<211>  6
<212>  PRT
<213>  Mus musculus

<400>  137

Gly Ser His Val Pro Tyr 
1               5       


<210>  138
<211>  8
<212>  PRT
<213>  Mus musculus

<400>  138

Phe Gln Gly Ser His Val Pro Tyr 
1               5               


<210>  139
<211>  117
<212>  PRT
<213>  Mus musculus

<400>  139

Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Met Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 
            20                  25                  30          


Asn Met His Trp Val Lys Gln Thr Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Thr Ile Tyr Pro Gly Asn Asp Asp Thr Ser Tyr Asn Gln Lys Phe 
    50                  55                  60                  


Lys Asp Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Ala Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Gly Gly Tyr Arg Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser 
            100                 105                 110         


Val Thr Val Ser Ser 
        115         


<210>  140
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  h5F9G4-VH IGHV1-3

<400>  140

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 
            20                  25                  30          


Asn Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Thr Ile Tyr Pro Gly Asn Asp Asp Thr Ser Tyr Asn Gln Lys Phe 
    50                  55                  60                  


Lys Asp Arg Val Thr Ile Thr Ala Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Gly Gly Tyr Arg Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu 
            100                 105                 110         


Val Thr Val Ser Ser 
        115         


<210>  141
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  VH graft IGHV5-51

<400>  141

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 
1               5                   10                  15      


Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Asn Tyr 
            20                  25                  30          


Asn Met His Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Thr Ile Tyr Pro Gly Asn Asp Asp Thr Ser Tyr Asn Gln Lys Phe 
    50                  55                  60                  


Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Gly Gly Tyr Arg Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu 
            100                 105                 110         


Val Thr Val Ser Ser 
        115         


<210>  142
<211>  112
<212>  PRT
<213>  Mus musculus

<400>  142

Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly 
1               5                   10                  15      


Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val Tyr Ser 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Gly Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr His Cys Phe Gln Gly 
                85                  90                  95      


Ser His Val Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105                 110         


<210>  143
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  h5F9G4-VL IGKV2-28

<400>  143

Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 
1               5                   10                  15      


Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val Tyr Ser 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Gly Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Phe Gln Gly 
                85                  90                  95      


Ser His Val Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  144
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  IGKV2-28

<400>  144

Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 
1               5                   10                  15      


Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val Tyr Ser 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Gly Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Phe Gln Gly 
                85                  90                  95      


Ser His Val Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  145
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR1

<400>  145

Arg Ser Ser Gln Ser Leu Leu His Ser Gly Gly Asn Thr Tyr Leu Asp 
1               5                   10                  15      


<210>  146
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR1

<400>  146

Arg Ser Ser Gln Ser Leu Leu His Ser Gly Gly Asn Thr Tyr Leu Gly 
1               5                   10                  15      


<210>  147
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR1

<400>  147

Arg Ser Ser Gln Ser Leu Leu His Ser Gly Tyr Asn Thr Tyr Leu Gly 
1               5                   10                  15      


<210>  148
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR1

<400>  148

Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Asn Thr Tyr Leu Asp 
1               5                   10                  15      


<210>  149
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR1

<400>  149

Arg Ser Ser Gln Ser Leu Leu His Ser Asn Tyr Asn Thr Tyr Leu Gly 
1               5                   10                  15      


<210>  150
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR1

<400>  150

Arg Ser Ser Gln Ser Leu Leu Gln Ser Asn Gly Asn Thr Tyr Leu Gly 
1               5                   10                  15      


<210>  151
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR1

<400>  151

Arg Ser Ser Gln Ser Leu Leu Tyr Ser Gly Gly Asn Thr Tyr Leu Gly 
1               5                   10                  15      


<210>  152
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR1

<400>  152

Arg Ser Ser Gln Ser Leu Leu Tyr Ser Asn Gly Asn Thr Tyr Leu Gly 
1               5                   10                  15      


<210>  153
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR1

<400>  153

Arg Ser Ser Gln Ser Leu Val His Ser Gly Gly Asn Thr Tyr Leu Gly 
1               5                   10                  15      


<210>  154
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR1

<400>  154

Arg Ser Ser Gln Ser Leu Val His Ser Gly Tyr Asn Thr Tyr Leu Gly 
1               5                   10                  15      


<210>  155
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR1

<400>  155

Arg Ser Ser Gln Ser Leu Val His Ser Asn Gly Asn Thr Tyr Leu Asp 
1               5                   10                  15      


<210>  156
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR1

<400>  156

Arg Ser Ser Gln Ser Leu Val His Ser Asn Gly Asn Thr Tyr Leu Gly 
1               5                   10                  15      


<210>  157
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR1

<400>  157

Arg Ser Ser Gln Ser Leu Val His Ser Asn Gly Gln Thr Tyr Leu Gly 
1               5                   10                  15      


<210>  158
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR1

<400>  158

Arg Ser Ser Gln Ser Leu Val His Ser Asn Tyr Asn Thr Tyr Leu Gly 
1               5                   10                  15      


<210>  159
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR1

<400>  159

Arg Ser Ser Gln Ser Leu Val His Ser Ser Gly Asn Thr Tyr Leu Gly 
1               5                   10                  15      


<210>  160
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR1

<400>  160

Arg Ser Ser Gln Ser Leu Val Gln Ser Asn Gly Asn Thr Tyr Leu Gly 
1               5                   10                  15      


<210>  161
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR1

<400>  161

Arg Ser Ser Gln Ser Leu Val Tyr Ser Asn Gly Asn Thr Tyr Leu Gly 
1               5                   10                  15      


<210>  162
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR1

<400>  162

Arg Ser Ser Gln Ser Leu Val Tyr Ser Asn Tyr Asn Thr Tyr Leu Gly 
1               5                   10                  15      


<210>  163
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR2

<400>  163

Lys Val Ser Asn Arg Ala Ser 
1               5           


<210>  164
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR2

<400>  164

Lys Val Ser Asn Arg Ser Ser 
1               5           


<210>  165
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR3

<400>  165

Phe Gln Ala Leu His Val Pro Tyr Thr 
1               5                   


<210>  166
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR3

<400>  166

Phe Gln Ala Met Gln Thr Pro Tyr Thr 
1               5                   


<210>  167
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR3

<400>  167

Phe Gln Ala Ser His Ile Pro Tyr Thr 
1               5                   


<210>  168
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR3

<400>  168

Phe Gln Ala Ser His Thr Pro Tyr Thr 
1               5                   


<210>  169
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR3

<400>  169

Phe Gln Ala Ser Gln Ile Pro Tyr Thr 
1               5                   


<210>  170
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR3

<400>  170

Phe Gln Ala Ser Gln Thr Pro Tyr Thr 
1               5                   


<210>  171
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR3

<400>  171

Phe Gln Ala Ser Arg Val Pro Tyr Thr 
1               5                   


<210>  172
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR3

<400>  172

Phe Gln Ala Thr Gln Val Pro Tyr Thr 
1               5                   


<210>  173
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR3

<400>  173

Phe Gln Gly Leu Gln Val Pro Tyr Thr 
1               5                   


<210>  174
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR3

<400>  174

Phe Gln Gly Ser His Ile Pro Tyr Thr 
1               5                   


<210>  175
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR3

<400>  175

Phe Gln Gly Ser His Thr Pro Tyr Thr 
1               5                   


<210>  176
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR3

<400>  176

Phe Gln Gly Ser Gln Thr Pro Tyr Thr 
1               5                   


<210>  177
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR3

<400>  177

Phe Gln Gly Ser Gln Val Pro Tyr Thr 
1               5                   


<210>  178
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR3

<400>  178

Leu Gln Gly Ser His Ile Pro Tyr Thr 
1               5                   


<210>  179
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR3

<400>  179

Leu Gln Gly Ser His Thr Pro Tyr Thr 
1               5                   


<210>  180
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR3

<400>  180

Leu Gln Gly Ser His Val Pro Tyr Thr 
1               5                   


<210>  181
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR3

<400>  181

Leu Gln Gly Ser Gln Thr Pro Tyr Thr 
1               5                   


<210>  182
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR3

<400>  182

Leu Gln Gly Ser Gln Val Pro Tyr Thr 
1               5                   


<210>  183
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR3

<400>  183

Met Gln Ala Leu Gln Val Pro Tyr Thr 
1               5                   


<210>  184
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR3

<400>  184

Met Gln Ala Ser His Ile Pro Tyr Thr 
1               5                   


<210>  185
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR3

<400>  185

Met Gln Ala Ser His Thr Pro Tyr Thr 
1               5                   


<210>  186
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR3

<400>  186

Met Gln Ala Ser Gln Ile Pro Tyr Thr 
1               5                   


<210>  187
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR3

<400>  187

Met Gln Ala Ser Gln Thr Pro Tyr Thr 
1               5                   


<210>  188
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR3

<400>  188

Met Gln Gly Leu His Val Pro Tyr Thr 
1               5                   


<210>  189
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR3

<400>  189

Met Gln Gly Leu Gln Val Pro Tyr Thr 
1               5                   


<210>  190
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR3

<400>  190

Met Gln Gly Ser His Ile Pro Tyr Thr 
1               5                   


<210>  191
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR3

<400>  191

Met Gln Gly Ser His Thr Pro Tyr Thr 
1               5                   


<210>  192
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR3

<400>  192

Met Gln Gly Ser Gln Ile Pro Tyr Thr 
1               5                   


<210>  193
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR3

<400>  193

Met Gln Gly Ser Gln Thr Pro Tyr Thr 
1               5                   


<210>  194
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR3

<400>  194

Met Gln Gly Ser Gln Val Pro Tyr Thr 
1               5                   


<210>  195
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR1

<400>  195

Gly Tyr Ser Phe Thr Asn Tyr Asn Ile Gly 
1               5                   10  


<210>  196
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR1

<400>  196

Gly Tyr Ser Phe Thr Asn Tyr Asn Met His 
1               5                   10  


<210>  197
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR1

<400>  197

Gly Tyr Ser Phe Thr Asn Tyr Ser Ile His 
1               5                   10  


<210>  198
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR1

<400>  198

Gly Tyr Ser Phe Thr Ser Tyr Asn Ile His 
1               5                   10  


<210>  199
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR1

<400>  199

Gly Tyr Ser Phe Thr Ser Tyr Asn Met His 
1               5                   10  


<210>  200
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  200

Ile Gly Thr Ile Tyr Pro Gly Asp Asp Asp Thr Arg Tyr Asn Pro Lys 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  201
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  201

Met Gly Ile Ile Tyr Pro Gly Asp Asp Asp Thr Arg Tyr Asn Pro Lys 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  202
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  202

Met Gly Ile Ile Tyr Pro Gly Asp Asp Asp Thr Arg Tyr Asn Pro Ser 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  203
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  203

Met Gly Ile Ile Tyr Pro Gly Asp Asp Asp Thr Ser Tyr Asn Pro Lys 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  204
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  204

Met Gly Ile Ile Tyr Pro Gly Asp Asp Asp Thr Ser Tyr Asn Gln Lys 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  205
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  205

Met Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Asn Pro Lys 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  206
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  206

Met Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Asn Pro Ser 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  207
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  207

Met Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Asn Gln Lys 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  208
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  208

Met Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Ser Tyr Asn Gln Ser 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  209
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  209

Met Gly Ile Ile Tyr Pro Gly Asn Asp Asp Thr Arg Tyr Asn Pro Lys 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  210
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  210

Met Gly Ile Ile Tyr Pro Gly Asn Asp Asp Thr Arg Tyr Asn Pro Ser 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  211
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  211

Met Gly Ile Ile Tyr Pro Gly Asn Asp Asp Thr Arg Tyr Asn Gln Lys 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  212
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  212

Met Gly Ile Ile Tyr Pro Gly Asn Ser Asp Thr Arg Tyr Asn Pro Lys 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  213
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  213

Met Gly Ile Ile Tyr Pro Gly Asn Ser Asp Thr Arg Tyr Asn Pro Ser 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  214
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  214

Met Gly Ile Ile Tyr Pro Gly Asn Ser Asp Thr Arg Tyr Asn Gln Lys 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  215
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  215

Met Gly Ile Ile Tyr Pro Gly Asn Ser Asp Thr Arg Tyr Asn Gln Arg 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  216
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  216

Met Gly Ile Ile Tyr Pro Gly Asn Ser Asp Thr Arg Tyr Asn Gln Ser 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  217
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  217

Met Gly Ile Ile Tyr Pro Gly Asn Ser Asp Thr Arg Tyr Ser Pro Lys 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  218
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  218

Met Gly Ile Ile Tyr Pro Gly Asn Ser Asp Thr Arg Tyr Ser Pro Ser 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  219
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  219

Met Gly Ile Ile Tyr Pro Gly Asn Ser Asp Thr Ser Tyr Asn Pro Lys 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  220
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  220

Met Gly Ile Ile Tyr Pro Gly Asn Ser Asp Thr Ser Tyr Asn Pro Arg 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  221
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  221

Met Gly Ile Ile Tyr Pro Gly Asn Ser Asp Thr Ser Tyr Asn Pro Ser 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  222
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  222

Met Gly Ile Ile Tyr Pro Gly Asn Ser Asp Thr Ser Tyr Asn Gln Lys 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  223
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  223

Met Gly Ile Ile Tyr Pro Gly Asn Ser Asp Thr Ser Tyr Ser Pro Lys 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  224
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  224

Met Gly Thr Ile Tyr Pro Gly Asp Asp Asp Thr Arg Tyr Asn Pro Lys 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  225
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  225

Met Gly Thr Ile Tyr Pro Gly Asp Asp Asp Thr Arg Tyr Asn Pro Ser 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  226
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  226

Met Gly Thr Ile Tyr Pro Gly Asp Asp Asp Thr Arg Tyr Asn Gln Lys 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  227
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  227

Met Gly Thr Ile Tyr Pro Gly Asp Asp Asp Thr Arg Tyr Asn Gln Asn 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  228
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  228

Met Gly Thr Ile Tyr Pro Gly Asp Asp Asp Thr Arg Tyr Asn Gln Ser 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  229
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  229

Met Gly Thr Ile Tyr Pro Gly Asp Asp Asp Thr Arg Tyr Ser Pro Lys 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  230
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  230

Met Gly Thr Ile Tyr Pro Gly Asp Asp Asp Thr Arg Tyr Ser Pro Ser 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  231
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  231

Met Gly Thr Ile Tyr Pro Gly Asp Asp Asp Thr Arg Tyr Ser Gln Lys 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  232
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  232

Met Gly Thr Ile Tyr Pro Gly Asp Asp Asp Thr Ser Tyr Ser Gln Lys 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  233
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  233

Met Gly Thr Ile Tyr Pro Gly Asp Gly Asp Thr Ser Tyr Asn Pro Ser 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  234
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  234

Met Gly Thr Ile Tyr Pro Gly Asp Asn Asp Thr Ser Tyr Asn Pro Ser 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  235
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  235

Met Gly Thr Ile Tyr Pro Gly Asp Ser Asp Thr Lys Tyr Asn Pro Lys 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  236
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  236

Met Gly Thr Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Asn Pro Ser 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  237
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  237

Met Gly Thr Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Lys 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  238
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  238

Met Gly Thr Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Arg 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  239
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  239

Met Gly Thr Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  240
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  240

Met Gly Thr Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Gln Lys 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  241
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  241

Met Gly Thr Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Gln Ser 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  242
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  242

Met Gly Thr Ile Tyr Pro Gly Asp Ser Asp Thr Ser Tyr Asn His Lys 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  243
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  243

Met Gly Thr Ile Tyr Pro Gly Asp Ser Asp Thr Ser Tyr Asn Pro Lys 
1               5                   10                  15      


Phe His Gly 
            


<210>  244
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  244

Met Gly Thr Ile Tyr Pro Gly Asp Ser Asp Thr Ser Tyr Asn Pro Arg 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  245
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  245

Met Gly Thr Ile Tyr Pro Gly Asp Ser Asp Thr Ser Tyr Asn Pro Ser 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  246
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  246

Met Gly Thr Ile Tyr Pro Gly Asp Ser Asp Thr Ser Tyr Asn Gln Lys 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  247
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  247

Met Gly Thr Ile Tyr Pro Gly Asp Ser Asp Thr Ser Tyr Asn Gln Ser 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  248
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  248

Met Gly Thr Ile Tyr Pro Gly Asp Ser Asp Thr Ser Tyr Ser Pro Lys 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  249
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  249

Met Gly Thr Ile Tyr Pro Gly Asp Ser Asp Thr Ser Tyr Ser Pro Ser 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  250
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  250

Met Gly Thr Ile Tyr Pro Gly Asp Ser Asp Thr Ser Tyr Ser Gln Lys 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  251
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  251

Met Gly Thr Ile Tyr Pro Gly Asn Asp Asp Thr Lys Tyr Ser Pro Lys 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  252
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  252

Met Gly Thr Ile Tyr Pro Gly Asn Asp Asp Thr Arg Tyr Asn Pro Lys 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  253
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  253

Met Gly Thr Ile Tyr Pro Gly Asn Asp Asp Thr Arg Tyr Asn Pro Ser 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  254
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  254

Met Gly Thr Ile Tyr Pro Gly Asn Asp Asp Thr Arg Tyr Asn Gln Lys 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  255
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  255

Met Gly Thr Ile Tyr Pro Gly Asn Asp Asp Thr Arg Tyr Asn Gln Ser 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  256
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  256

Met Gly Thr Ile Tyr Pro Gly Asn Asp Asp Thr Arg Tyr Ser Pro Lys 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  257
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  257

Met Gly Thr Ile Tyr Pro Gly Asn Asp Asp Thr Arg Tyr Ser Pro Ser 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  258
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  258

Met Gly Thr Ile Tyr Pro Gly Asn Asp Asp Thr Arg Tyr Ser Gln Lys 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  259
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  259

Met Gly Thr Ile Tyr Pro Gly Asp Asp Asp Thr Ser Tyr Asn Pro Lys 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  260
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  260

Met Gly Thr Ile Tyr Pro Gly Asp Asp Asp Thr Ser Tyr Asn Pro Ser 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  261
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  261

Met Gly Thr Ile Tyr Pro Gly Asp Asp Asp Thr Ser Tyr Asn Gln Lys 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  262
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  262

Met Gly Thr Ile Tyr Pro Gly Asn Asp Asp Thr Ser Tyr Asn Gln Ser 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  263
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  263

Met Gly Thr Ile Tyr Pro Gly Asn Asp Asp Thr Ser Tyr Ser Pro Lys 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  264
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  264

Met Gly Thr Ile Tyr Pro Gly Asn Asp Asp Thr Ser Tyr Ser Pro Arg 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  265
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  265

Met Gly Thr Ile Tyr Pro Gly Asn Asp Asp Thr Ser Tyr Ser Pro Ser 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  266
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  266

Met Gly Thr Ile Tyr Pro Gly Asn Asp Asp Thr Ser Tyr Ser Gln Ser 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  267
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  267

Met Gly Thr Ile Tyr Pro Gly Asn Asp Gly Thr Arg Tyr Asn Gln Lys 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  268
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  268

Met Gly Thr Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Asn His Lys 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  269
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  269

Met Gly Thr Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Asn Gln Lys 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  270
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  270

Met Gly Thr Ile Tyr Pro Gly Asn Asn Asp Thr Ser Tyr Asn Pro Lys 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  271
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  271

Met Gly Thr Ile Tyr Pro Gly Asn Ser Asp Thr Arg Tyr Asn His Ser 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  272
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  272

Met Gly Thr Ile Tyr Pro Gly Asn Ser Asp Thr Arg Tyr Asn Pro Ser 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  273
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  273

Met Gly Thr Ile Tyr Pro Gly Asn Ser Asp Thr Arg Tyr Asn Gln Lys 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  274
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  274

Met Gly Thr Ile Tyr Pro Gly Asn Ser Asp Thr Arg Tyr Asn Gln Ser 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  275
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  275

Met Gly Thr Ile Tyr Pro Gly Asn Ser Asp Thr Arg Tyr Ser Pro Lys 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  276
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  276

Met Gly Thr Ile Tyr Pro Gly Asn Ser Asp Thr Arg Tyr Ser Pro Ser 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  277
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  277

Met Gly Thr Ile Tyr Pro Gly Asn Ser Asp Thr Arg Tyr Ser Gln Lys 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  278
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  278

Met Gly Thr Ile Tyr Pro Gly Asn Ser Asp Thr Ser Tyr Asn Pro Arg 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  279
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  279

Met Gly Thr Ile Tyr Pro Gly Asn Ser Asp Thr Ser Tyr Asn Gln Lys 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  280
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  280

Met Gly Thr Ile Tyr Pro Gly Asn Ser Asp Thr Ser Tyr Asn Gln Ser 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  281
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  281

Met Gly Thr Ile Tyr Pro Gly Asn Ser Asp Thr Ser Tyr Ser Pro Lys 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  282
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  282

Met Gly Thr Ile Tyr Pro Gly Asn Ser Asp Thr Ser Tyr Ser Pro Ser 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  283
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  283

Met Gly Thr Ile Tyr Pro Gly Asn Ser Asp Thr Ser Tyr Ser Gln Lys 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  284
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  284

Met Gly Thr Ile Tyr Ser Gly Asn Ser Asp Thr Ser Tyr Ser Pro Ser 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  285
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  285

Met Gly Thr Ile Tyr Pro Gly Asn Asp Asp Thr Arg Tyr Ser Gln Ser 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  286
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  286

Met Gly Thr Ile Tyr Pro Gly Asn Asp Asp Thr Ser Tyr Asn His Lys 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  287
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  287

Met Gly Thr Ile Tyr Pro Gly Asn Asp Asp Thr Ser Tyr Asn Pro Lys 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  288
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  288

Met Gly Thr Ile Tyr Pro Gly Asn Asp Asp Thr Ser Tyr Asn Pro Ser 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  289
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR3

<400>  289

Gly Gly Ala Arg Ala Met Asp Tyr 
1               5               


<210>  290
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR3

<400>  290

Gly Gly Cys Arg Ala Leu Asp Tyr 
1               5               


<210>  291
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR3

<400>  291

Gly Gly Cys Arg Ala Met Asp Tyr 
1               5               


<210>  292
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR3

<400>  292

Gly Gly Cys Arg Ala Met Gly Tyr 
1               5               


<210>  293
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR3

<400>  293

Gly Gly Asp Arg Ala Met Asp Tyr 
1               5               


<210>  294
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR3

<400>  294

Gly Gly Glu Arg Ala Met Asp Tyr 
1               5               


<210>  295
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR3

<400>  295

Gly Gly Phe Arg Ala Glu Asp Tyr 
1               5               


<210>  296
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR3

<400>  296

Gly Gly Phe Arg Ala Gln Asp Tyr 
1               5               


<210>  297
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR3

<400>  297

Gly Gly Gly Arg Ala Met Asp Tyr 
1               5               


<210>  298
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR3

<400>  298

Gly Gly His Arg Ala Glu Asp Tyr 
1               5               


<210>  299
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR3

<400>  299

Gly Gly His Arg Ala Met Asp Tyr 
1               5               


<210>  300
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR3

<400>  300

Gly Gly Leu Arg Ala Met Asp Tyr 
1               5               


<210>  301
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR3

<400>  301

Gly Gly Leu Arg Thr Met Asp Tyr 
1               5               


<210>  302
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR3

<400>  302

Gly Gly Met Arg Ala Met Asp Tyr 
1               5               


<210>  303
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR3

<400>  303

Gly Gly Asn Arg Ala Lys Asp Tyr 
1               5               


<210>  304
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR3

<400>  304

Gly Gly Asn Arg Ala Met Asp Tyr 
1               5               


<210>  305
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR3

<400>  305

Gly Gly Gln Arg Ala Met Asp Tyr 
1               5               


<210>  306
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR3

<400>  306

Gly Gly Arg Arg Ala Met Asp Tyr 
1               5               


<210>  307
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR3

<400>  307

Gly Gly Ser Arg Ala Lys Asp Tyr 
1               5               


<210>  308
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR3

<400>  308

Gly Gly Ser Arg Ala Met Asp Tyr 
1               5               


<210>  309
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR3

<400>  309

Gly Gly Thr Arg Ala Met Asp Tyr 
1               5               


<210>  310
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR3

<400>  310

Gly Gly Val Arg Ala Thr Asp Tyr 
1               5               


<210>  311
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR3

<400>  311

Gly Gly Trp Arg Ala Met Asp Tyr 
1               5               


<210>  312
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR3

<400>  312

Gly Gly Tyr His Ala Met Asp Tyr 
1               5               


<210>  313
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR3

<400>  313

Gly Gly Tyr Lys Ala Met Asp Tyr 
1               5               


<210>  314
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR3

<400>  314

Gly Gly Tyr Arg Ala Ala Asp Tyr 
1               5               


<210>  315
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR3

<400>  315

Gly Gly Tyr Arg Ala Leu Asp Tyr 
1               5               


<210>  316
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR3

<400>  316

Gly Gly Tyr Arg Ala Pro Asp Tyr 
1               5               


<210>  317
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR3

<400>  317

Gly Gly Tyr Arg Ala Arg Asp Tyr 
1               5               


<210>  318
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR3

<400>  318

Gly Gly Tyr Arg Ala Ser Asp Tyr 
1               5               


<210>  319
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR3

<400>  319

Gly Gly Tyr Arg Ala Thr Asp Tyr 
1               5               


<210>  320
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR3

<400>  320

Gly Gly Tyr Arg Ala Val Asp Tyr 
1               5               


<210>  321
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR3

<400>  321

Gly Gly Tyr Arg Ile Met Asp Tyr 
1               5               


<210>  322
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR3

<400>  322

Gly Gly Tyr Arg Thr Glu Asp Tyr 
1               5               


<210>  323
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR3

<400>  323

Gly Gly Tyr Arg Thr Met Asp Tyr 
1               5               


<210>  324
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR3

<400>  324

Gly Gly Tyr Arg Thr Thr Asp Tyr 
1               5               


<210>  325
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR3

<400>  325

Gly Gly Tyr Arg Val Met Asp Tyr 
1               5               


<210>  326
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR3

<400>  326

Gly Gly Tyr Arg Trp Met Asp Tyr 
1               5               


<210>  327
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR3

<400>  327

Gln Gly Tyr Arg Ala Met Asp Tyr 
1               5               


<210>  328
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR1

<400>  328

Arg Ser Ser Gln Ser Leu Leu His Ser Lys Gly Asn Thr Tyr Leu Gly 
1               5                   10                  15      


<210>  329
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR1

<400>  329

Arg Ser Ser Gln Ser Leu Leu His Ser Asn Tyr Asn Thr Tyr Leu Gly 
1               5                   10                  15      


<210>  330
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion LCDR2

<400>  330

Lys Gly Ser Asn Arg Ala Ser 
1               5           


<210>  331
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  331

Met Gly Thr Ile Tyr Pro Gly Asn Ser Asp Thr Ser Tyr Asn His Lys 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  332
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR2

<400>  332

Met Gly Thr Ile Tyr Pro Gly Asn Asp Asn Thr Lys Tyr Asn Gln Lys 
1               5                   10                  15      


Phe Gln Gly 
            


<210>  333
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  anti-CD47 antibody molecule or antigen-binding portion HCDR3

<400>  333

Gly Gly Asn Arg Ala Glu Asp Tyr 
1               5               


